Coronaviruses have caused several human epidemics and pandemics including the
ongoing coronavirus disease 2019 (COVID-19). Prophylactic vaccines and therapeutic …

The identification of the Omicron (B. 1.1. 529.1 or BA. 1) variant of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) in Botswana in November 2021 1 immediately …

A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-
CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we …

Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

In the absence of virus-targeting small-molecule drugs approved for the treatment and
prevention of COVID-19, broadening the repertoire of potent SARS-CoV-2-neutralizing …

The Omicron variant is rapidly becoming the dominant SARS-CoV-2 virus circulating
globally. It is important to define reductions in virus neutralizing activity in the serum of …

SARS-CoV-2 Omicron subvariants have evolved to evade receptor-binding site (RBS)
antibodies that exist in diverse individuals as public antibody clones. We rationally selected …

The Omicron BA. 1 variant of SARS-CoV-2 escapes convalescent sera and monoclonal
antibodies that are effective against earlier strains of the virus. This immune evasion is …

Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …

Abstract The Omicron (B. 1.1. 529) variant of SARS-CoV-2 emerged in November 2021 and
is rapidly spreading among the human population. Although recent reports reveal that the …